| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 24 | 2024 | 544 | 4.080 |
Why?
|
| Flow Cytometry | 24 | 2024 | 1159 | 3.040 |
Why?
|
| Mouth Neoplasms | 8 | 2024 | 85 | 1.520 |
Why?
|
| Carcinoma, Squamous Cell | 16 | 2024 | 627 | 1.510 |
Why?
|
| Neoplasms | 12 | 2024 | 2455 | 1.480 |
Why?
|
| Unsupervised Machine Learning | 2 | 2021 | 18 | 1.420 |
Why?
|
| Germinal Center | 3 | 2022 | 57 | 1.300 |
Why?
|
| Single-Cell Analysis | 6 | 2022 | 274 | 1.290 |
Why?
|
| Surgery, Computer-Assisted | 6 | 2020 | 77 | 1.250 |
Why?
|
| Glioblastoma | 2 | 2023 | 322 | 1.190 |
Why?
|
| Lymphoma, Follicular | 7 | 2017 | 39 | 1.170 |
Why?
|
| Cone-Beam Computed Tomography | 5 | 2020 | 30 | 1.170 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2021 | 114 | 1.040 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2023 | 596 | 1.040 |
Why?
|
| Melanoma | 4 | 2021 | 730 | 1.010 |
Why?
|
| Mass Spectrometry | 3 | 2019 | 714 | 0.990 |
Why?
|
| Image Cytometry | 2 | 2022 | 7 | 0.980 |
Why?
|
| B-Lymphocytes | 4 | 2022 | 816 | 0.970 |
Why?
|
| Photochemotherapy | 3 | 2024 | 32 | 0.940 |
Why?
|
| Endoscopy | 2 | 2020 | 288 | 0.930 |
Why?
|
| Receptors, Antigen, B-Cell | 5 | 2022 | 126 | 0.890 |
Why?
|
| Ontario | 12 | 2025 | 90 | 0.860 |
Why?
|
| Signal Transduction | 18 | 2021 | 4931 | 0.860 |
Why?
|
| Monocytes | 4 | 2022 | 553 | 0.800 |
Why?
|
| Humans | 117 | 2025 | 129625 | 0.770 |
Why?
|
| Nanoparticles | 3 | 2024 | 375 | 0.760 |
Why?
|
| Proteomics | 5 | 2022 | 1055 | 0.760 |
Why?
|
| Myeloid-Derived Suppressor Cells | 2 | 2021 | 64 | 0.740 |
Why?
|
| Temporal Bone | 3 | 2013 | 49 | 0.740 |
Why?
|
| Picornaviridae Infections | 1 | 2021 | 45 | 0.710 |
Why?
|
| Skull Base | 2 | 2013 | 46 | 0.710 |
Why?
|
| Optical Imaging | 2 | 2020 | 56 | 0.710 |
Why?
|
| Nasal Surgical Procedures | 1 | 2020 | 6 | 0.690 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2020 | 2512 | 0.680 |
Why?
|
| Monitoring, Intraoperative | 2 | 2013 | 47 | 0.670 |
Why?
|
| CD40 Antigens | 2 | 2019 | 88 | 0.670 |
Why?
|
| Cells | 1 | 2020 | 24 | 0.660 |
Why?
|
| Masks | 1 | 2020 | 60 | 0.660 |
Why?
|
| Tumor Microenvironment | 8 | 2023 | 627 | 0.640 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2018 | 210 | 0.640 |
Why?
|
| Education | 1 | 2020 | 101 | 0.640 |
Why?
|
| Fluorescent Dyes | 1 | 2021 | 312 | 0.640 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2017 | 1336 | 0.630 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 277 | 0.620 |
Why?
|
| CD40 Ligand | 1 | 2019 | 38 | 0.620 |
Why?
|
| Monitoring, Immunologic | 1 | 2018 | 23 | 0.610 |
Why?
|
| Nestin | 1 | 2018 | 19 | 0.600 |
Why?
|
| Contrast Media | 2 | 2020 | 393 | 0.590 |
Why?
|
| Phagocytes | 1 | 2019 | 97 | 0.590 |
Why?
|
| Airway Obstruction | 1 | 2019 | 152 | 0.580 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 131 | 0.580 |
Why?
|
| Immunologic Memory | 2 | 2021 | 349 | 0.570 |
Why?
|
| Biomarkers, Tumor | 11 | 2021 | 1164 | 0.560 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 295 | 0.560 |
Why?
|
| Organ Transplantation | 1 | 2020 | 228 | 0.550 |
Why?
|
| Phosphorylation | 10 | 2022 | 1713 | 0.550 |
Why?
|
| Occupational Exposure | 1 | 2020 | 299 | 0.530 |
Why?
|
| Pandemics | 3 | 2023 | 1491 | 0.520 |
Why?
|
| Machine Learning | 2 | 2018 | 443 | 0.510 |
Why?
|
| Macrophages | 2 | 2023 | 1488 | 0.500 |
Why?
|
| Algorithms | 8 | 2021 | 1616 | 0.490 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 340 | 0.490 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 334 | 0.490 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2021 | 204 | 0.490 |
Why?
|
| Dendritic Cells | 1 | 2019 | 481 | 0.480 |
Why?
|
| Specialties, Surgical | 1 | 2016 | 74 | 0.470 |
Why?
|
| Breast | 1 | 2016 | 153 | 0.470 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 506 | 0.470 |
Why?
|
| Estrogen Receptor alpha | 1 | 2016 | 130 | 0.460 |
Why?
|
| Neoplasm Staging | 5 | 2022 | 1282 | 0.460 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 1145 | 0.450 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2016 | 124 | 0.450 |
Why?
|
| Models, Theoretical | 1 | 2018 | 546 | 0.440 |
Why?
|
| Lymphocytes | 3 | 2023 | 378 | 0.440 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2013 | 18 | 0.430 |
Why?
|
| Estrogens | 1 | 2016 | 347 | 0.410 |
Why?
|
| Rabbits | 4 | 2024 | 779 | 0.410 |
Why?
|
| Cadaver | 7 | 2022 | 308 | 0.400 |
Why?
|
| Aged | 34 | 2024 | 22061 | 0.400 |
Why?
|
| Middle Aged | 40 | 2024 | 31136 | 0.400 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 122 | 0.390 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 887 | 0.390 |
Why?
|
| Software | 5 | 2023 | 608 | 0.380 |
Why?
|
| Nuclear Proteins | 3 | 2016 | 660 | 0.380 |
Why?
|
| T-Lymphocytes | 2 | 2024 | 1936 | 0.370 |
Why?
|
| Lateral Ventricles | 2 | 2023 | 36 | 0.360 |
Why?
|
| Surgical Procedures, Operative | 3 | 2024 | 244 | 0.350 |
Why?
|
| Adult | 36 | 2024 | 35599 | 0.350 |
Why?
|
| Internet | 3 | 2015 | 618 | 0.350 |
Why?
|
| Female | 52 | 2025 | 68734 | 0.350 |
Why?
|
| Databases as Topic | 1 | 2010 | 59 | 0.340 |
Why?
|
| Photosensitizing Agents | 2 | 2024 | 31 | 0.340 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2022 | 855 | 0.340 |
Why?
|
| Disease-Free Survival | 10 | 2021 | 646 | 0.340 |
Why?
|
| Reproducibility of Results | 10 | 2021 | 3080 | 0.330 |
Why?
|
| Lymphocyte Subsets | 1 | 2010 | 84 | 0.330 |
Why?
|
| Equipment Design | 5 | 2020 | 514 | 0.330 |
Why?
|
| Male | 49 | 2024 | 63670 | 0.330 |
Why?
|
| Prognosis | 16 | 2022 | 3774 | 0.330 |
Why?
|
| Referral and Consultation | 2 | 2025 | 730 | 0.320 |
Why?
|
| Phosphoproteins | 3 | 2016 | 335 | 0.320 |
Why?
|
| Aged, 80 and over | 22 | 2024 | 7052 | 0.320 |
Why?
|
| Immunophenotyping | 4 | 2024 | 311 | 0.310 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2006 | 47 | 0.310 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2021 | 958 | 0.310 |
Why?
|
| Oximes | 2 | 2018 | 22 | 0.300 |
Why?
|
| Publishing | 1 | 2010 | 140 | 0.300 |
Why?
|
| DNA, Neoplasm | 4 | 2016 | 157 | 0.300 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2008 | 23 | 0.290 |
Why?
|
| Leukemia | 3 | 2021 | 229 | 0.290 |
Why?
|
| Pyrimidinones | 2 | 2018 | 102 | 0.280 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2004 | 17 | 0.280 |
Why?
|
| Quality Improvement | 1 | 2016 | 1101 | 0.280 |
Why?
|
| STAT1 Transcription Factor | 3 | 2022 | 69 | 0.280 |
Why?
|
| Mutation | 8 | 2024 | 3717 | 0.280 |
Why?
|
| Imidazoles | 2 | 2018 | 234 | 0.280 |
Why?
|
| Porphyrins | 3 | 2015 | 21 | 0.270 |
Why?
|
| MAP Kinase Signaling System | 2 | 2006 | 313 | 0.270 |
Why?
|
| Pyridones | 2 | 2018 | 158 | 0.270 |
Why?
|
| Cell Communication | 2 | 2024 | 301 | 0.270 |
Why?
|
| Adenocarcinoma | 3 | 2023 | 893 | 0.270 |
Why?
|
| Surgical Wound Infection | 3 | 2019 | 283 | 0.270 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2006 | 50 | 0.260 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2006 | 326 | 0.260 |
Why?
|
| Phenotype | 5 | 2022 | 3075 | 0.260 |
Why?
|
| Cell Line, Tumor | 7 | 2021 | 3186 | 0.260 |
Why?
|
| Cells, Cultured | 8 | 2021 | 4084 | 0.260 |
Why?
|
| Otologic Surgical Procedures | 1 | 2006 | 18 | 0.250 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2022 | 546 | 0.250 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2006 | 74 | 0.250 |
Why?
|
| Tyrosine | 1 | 2006 | 223 | 0.250 |
Why?
|
| Waiting Lists | 2 | 2025 | 237 | 0.250 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2023 | 373 | 0.250 |
Why?
|
| Theranostic Nanomedicine | 2 | 2015 | 12 | 0.240 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 903 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2006 | 234 | 0.240 |
Why?
|
| Fluorescence | 3 | 2020 | 155 | 0.240 |
Why?
|
| Lymphoma, B-Cell | 1 | 2006 | 105 | 0.240 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2022 | 252 | 0.240 |
Why?
|
| Scapula | 2 | 2018 | 45 | 0.240 |
Why?
|
| Neutrophils | 2 | 2022 | 1210 | 0.230 |
Why?
|
| Carcinogenesis | 2 | 2019 | 213 | 0.230 |
Why?
|
| Metabolomics | 2 | 2022 | 653 | 0.230 |
Why?
|
| Animals | 18 | 2024 | 35391 | 0.230 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 576 | 0.230 |
Why?
|
| Precision Medicine | 3 | 2019 | 387 | 0.230 |
Why?
|
| Retrospective Studies | 17 | 2024 | 14522 | 0.230 |
Why?
|
| Herpesvirus 4, Human | 2 | 2004 | 156 | 0.230 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2013 | 528 | 0.220 |
Why?
|
| Nasopharynx | 1 | 2004 | 68 | 0.220 |
Why?
|
| Young Adult | 13 | 2024 | 12455 | 0.220 |
Why?
|
| Free Tissue Flaps | 2 | 2017 | 55 | 0.220 |
Why?
|
| DNA, Viral | 2 | 2010 | 347 | 0.220 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 2133 | 0.220 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2021 | 1058 | 0.210 |
Why?
|
| Survival Rate | 8 | 2021 | 1872 | 0.210 |
Why?
|
| Forkhead Transcription Factors | 1 | 2024 | 183 | 0.210 |
Why?
|
| Heterozygote | 1 | 2024 | 275 | 0.210 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2006 | 507 | 0.210 |
Why?
|
| Antineoplastic Agents | 5 | 2022 | 2046 | 0.210 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2025 | 137 | 0.210 |
Why?
|
| Cataract Extraction | 1 | 2024 | 97 | 0.210 |
Why?
|
| Gene Expression | 2 | 2006 | 1465 | 0.200 |
Why?
|
| Carcinoma | 1 | 2004 | 214 | 0.200 |
Why?
|
| Social Class | 1 | 2024 | 259 | 0.190 |
Why?
|
| HMGB1 Protein | 1 | 2022 | 49 | 0.190 |
Why?
|
| Cytokines | 4 | 2022 | 2021 | 0.190 |
Why?
|
| CD57 Antigens | 1 | 2021 | 16 | 0.190 |
Why?
|
| Eustachian Tube | 1 | 2022 | 8 | 0.190 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 851 | 0.190 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 129 | 0.190 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2022 | 17 | 0.190 |
Why?
|
| Extracellular Vesicles | 1 | 2024 | 129 | 0.190 |
Why?
|
| Ear Diseases | 1 | 2022 | 14 | 0.190 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 126 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 943 | 0.190 |
Why?
|
| Emergency Service, Hospital | 2 | 2024 | 1914 | 0.190 |
Why?
|
| Myositis | 1 | 2022 | 51 | 0.190 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2013 | 48 | 0.180 |
Why?
|
| Immunity | 1 | 2022 | 138 | 0.180 |
Why?
|
| Microscopy | 1 | 2023 | 141 | 0.180 |
Why?
|
| Lymph Nodes | 3 | 2020 | 472 | 0.180 |
Why?
|
| CD4 Antigens | 1 | 2021 | 137 | 0.180 |
Why?
|
| Rhinovirus | 1 | 2021 | 56 | 0.180 |
Why?
|
| Glutaminase | 1 | 2021 | 11 | 0.180 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 154 | 0.180 |
Why?
|
| Containment of Biohazards | 1 | 2020 | 12 | 0.180 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2021 | 50 | 0.180 |
Why?
|
| Palatine Tonsil | 2 | 2018 | 45 | 0.170 |
Why?
|
| Mouth | 2 | 2019 | 84 | 0.170 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2025 | 306 | 0.170 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 25 | 0.170 |
Why?
|
| Neoplasm Proteins | 4 | 2015 | 419 | 0.170 |
Why?
|
| Equipment Safety | 1 | 2020 | 37 | 0.170 |
Why?
|
| CD28 Antigens | 1 | 2020 | 48 | 0.170 |
Why?
|
| Fas Ligand Protein | 1 | 2020 | 58 | 0.170 |
Why?
|
| X-Ray Microtomography | 1 | 2020 | 84 | 0.170 |
Why?
|
| Nephritis | 1 | 2020 | 22 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 179 | 0.170 |
Why?
|
| HLA-DR Antigens | 1 | 2021 | 223 | 0.170 |
Why?
|
| Anemia, Aplastic | 1 | 2020 | 36 | 0.170 |
Why?
|
| Computational Biology | 2 | 2015 | 596 | 0.170 |
Why?
|
| Graft vs Host Disease | 2 | 2021 | 240 | 0.170 |
Why?
|
| Injections | 1 | 2020 | 174 | 0.170 |
Why?
|
| Supraglottitis | 1 | 2019 | 1 | 0.170 |
Why?
|
| Patient Care Team | 1 | 2025 | 600 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 1 | 2021 | 189 | 0.160 |
Why?
|
| Automation | 1 | 2020 | 81 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2013 | 67 | 0.160 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 198 | 0.160 |
Why?
|
| Vocal Cord Paralysis | 1 | 2019 | 29 | 0.160 |
Why?
|
| Laryngeal Diseases | 1 | 2019 | 28 | 0.160 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 88 | 0.160 |
Why?
|
| RNA, Viral | 2 | 2022 | 620 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 2342 | 0.160 |
Why?
|
| Croup | 1 | 2019 | 26 | 0.160 |
Why?
|
| Liposomes | 1 | 2020 | 171 | 0.160 |
Why?
|
| Mice | 9 | 2024 | 16961 | 0.160 |
Why?
|
| Pilot Projects | 2 | 2020 | 1592 | 0.160 |
Why?
|
| Models, Statistical | 3 | 2020 | 625 | 0.160 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 164 | 0.160 |
Why?
|
| Surgical Flaps | 2 | 2010 | 136 | 0.160 |
Why?
|
| Biological Products | 1 | 2022 | 205 | 0.160 |
Why?
|
| Up-Regulation | 3 | 2016 | 840 | 0.160 |
Why?
|
| Adenoids | 1 | 2018 | 12 | 0.150 |
Why?
|
| Operating Rooms | 1 | 2020 | 115 | 0.150 |
Why?
|
| STAT5 Transcription Factor | 3 | 2021 | 48 | 0.150 |
Why?
|
| Interleukin-2 | 1 | 2020 | 437 | 0.150 |
Why?
|
| Forecasting | 1 | 2020 | 361 | 0.150 |
Why?
|
| Dexamethasone | 1 | 2021 | 350 | 0.150 |
Why?
|
| Tuberous Sclerosis | 1 | 2019 | 49 | 0.150 |
Why?
|
| Organizational Objectives | 1 | 2018 | 73 | 0.150 |
Why?
|
| Antibodies, Neoplasm | 1 | 2018 | 34 | 0.150 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 119 | 0.150 |
Why?
|
| Maxillary Neoplasms | 1 | 2018 | 8 | 0.150 |
Why?
|
| Respiratory System | 1 | 2019 | 155 | 0.150 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2018 | 70 | 0.150 |
Why?
|
| Length of Stay | 2 | 2020 | 1122 | 0.150 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 179 | 0.150 |
Why?
|
| Physical Examination | 1 | 2019 | 234 | 0.150 |
Why?
|
| Ilium | 1 | 2018 | 29 | 0.150 |
Why?
|
| Papillomavirus Infections | 2 | 2013 | 297 | 0.150 |
Why?
|
| Astrocytoma | 1 | 2019 | 115 | 0.150 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 602 | 0.150 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 4894 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2022 | 1843 | 0.140 |
Why?
|
| Orbit | 1 | 2018 | 57 | 0.140 |
Why?
|
| Hospitalization | 3 | 2024 | 2057 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 250 | 0.140 |
Why?
|
| Survival Analysis | 4 | 2022 | 1269 | 0.140 |
Why?
|
| Mandibular Osteotomy | 1 | 2017 | 2 | 0.140 |
Why?
|
| Intubation, Intratracheal | 1 | 2019 | 242 | 0.140 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 142 | 0.140 |
Why?
|
| Bone Transplantation | 1 | 2018 | 84 | 0.140 |
Why?
|
| Proteins | 2 | 2019 | 944 | 0.140 |
Why?
|
| Neck Dissection | 2 | 2014 | 16 | 0.140 |
Why?
|
| Mandible | 1 | 2017 | 61 | 0.140 |
Why?
|
| Surgical Instruments | 1 | 2017 | 51 | 0.140 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 1109 | 0.130 |
Why?
|
| Immunoglobulin M | 3 | 2022 | 276 | 0.130 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2016 | 19 | 0.130 |
Why?
|
| Cohort Studies | 7 | 2023 | 5426 | 0.130 |
Why?
|
| Acute Disease | 1 | 2019 | 979 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 141 | 0.130 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 217 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 181 | 0.130 |
Why?
|
| Cell Line | 2 | 2021 | 2784 | 0.130 |
Why?
|
| Bone Plates | 1 | 2017 | 75 | 0.130 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 348 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 67 | 0.130 |
Why?
|
| Adolescent | 11 | 2024 | 20412 | 0.130 |
Why?
|
| Photoacoustic Techniques | 1 | 2015 | 5 | 0.130 |
Why?
|
| Time Factors | 3 | 2025 | 6555 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 858 | 0.120 |
Why?
|
| Parotid Neoplasms | 1 | 2015 | 16 | 0.120 |
Why?
|
| Parotid Gland | 1 | 2015 | 22 | 0.120 |
Why?
|
| Ablation Techniques | 1 | 2015 | 35 | 0.120 |
Why?
|
| Sepsis | 1 | 2022 | 575 | 0.120 |
Why?
|
| Uterus | 1 | 2016 | 207 | 0.120 |
Why?
|
| Treatment Outcome | 9 | 2018 | 10219 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2020 | 735 | 0.120 |
Why?
|
| Serpins | 1 | 2015 | 31 | 0.120 |
Why?
|
| Oncology Service, Hospital | 1 | 2015 | 16 | 0.120 |
Why?
|
| Chromatin | 2 | 2016 | 479 | 0.120 |
Why?
|
| Head | 1 | 2016 | 96 | 0.120 |
Why?
|
| Patient Readmission | 1 | 2020 | 653 | 0.120 |
Why?
|
| Skull Neoplasms | 1 | 2014 | 22 | 0.120 |
Why?
|
| Chondrosarcoma | 1 | 2014 | 15 | 0.120 |
Why?
|
| NF-kappa B | 1 | 2019 | 665 | 0.120 |
Why?
|
| Chordoma | 1 | 2014 | 14 | 0.120 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2014 | 34 | 0.120 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 162 | 0.120 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 151 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2018 | 744 | 0.110 |
Why?
|
| Genome | 1 | 2016 | 278 | 0.110 |
Why?
|
| Thyroid Neoplasms | 2 | 2012 | 312 | 0.110 |
Why?
|
| Biomimetic Materials | 1 | 2015 | 69 | 0.110 |
Why?
|
| Human papillomavirus 16 | 2 | 2013 | 34 | 0.110 |
Why?
|
| Gene Expression Profiling | 5 | 2017 | 1687 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2023 | 7135 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2021 | 2373 | 0.110 |
Why?
|
| Leukoplakia, Oral | 1 | 2014 | 8 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 1203 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 2 | 2015 | 378 | 0.110 |
Why?
|
| Information Dissemination | 2 | 2020 | 205 | 0.110 |
Why?
|
| Genital Neoplasms, Female | 1 | 2015 | 82 | 0.110 |
Why?
|
| Apoptosis | 2 | 2020 | 2492 | 0.110 |
Why?
|
| Immunohistochemistry | 6 | 2023 | 1685 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 757 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 708 | 0.100 |
Why?
|
| Lymphatic Metastasis | 4 | 2015 | 320 | 0.100 |
Why?
|
| Proto-Oncogenes | 1 | 1993 | 29 | 0.100 |
Why?
|
| Disability Evaluation | 1 | 2014 | 285 | 0.100 |
Why?
|
| Genes, ras | 1 | 1993 | 95 | 0.100 |
Why?
|
| Syk Kinase | 2 | 2016 | 21 | 0.100 |
Why?
|
| Disease Progression | 5 | 2014 | 2627 | 0.100 |
Why?
|
| Pediatrics | 1 | 2020 | 1056 | 0.100 |
Why?
|
| Clonal Evolution | 1 | 2013 | 39 | 0.100 |
Why?
|
| Papillomaviridae | 1 | 2013 | 114 | 0.100 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2023 | 740 | 0.100 |
Why?
|
| Palate, Hard | 1 | 2012 | 5 | 0.100 |
Why?
|
| Maxilla | 1 | 2012 | 33 | 0.100 |
Why?
|
| Hypertension, Pulmonary | 1 | 2023 | 1894 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2016 | 151 | 0.090 |
Why?
|
| ErbB Receptors | 2 | 2007 | 607 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2016 | 184 | 0.090 |
Why?
|
| Laryngeal Neoplasms | 2 | 2002 | 31 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2004 | 636 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2013 | 232 | 0.090 |
Why?
|
| Tongue Neoplasms | 1 | 2010 | 24 | 0.090 |
Why?
|
| Cluster Analysis | 3 | 2020 | 482 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 752 | 0.090 |
Why?
|
| DNA Damage | 2 | 2018 | 384 | 0.090 |
Why?
|
| CD79 Antigens | 2 | 2022 | 15 | 0.080 |
Why?
|
| Phantoms, Imaging | 2 | 2008 | 137 | 0.080 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2010 | 67 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2010 | 55 | 0.080 |
Why?
|
| Blood Loss, Surgical | 1 | 2010 | 93 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2021 | 208 | 0.080 |
Why?
|
| Models, Immunological | 1 | 2010 | 95 | 0.080 |
Why?
|
| Microsurgery | 1 | 2010 | 70 | 0.080 |
Why?
|
| Extracellular Space | 1 | 2010 | 120 | 0.080 |
Why?
|
| Biomarkers | 4 | 2022 | 3968 | 0.080 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2009 | 26 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2022 | 869 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 106 | 0.080 |
Why?
|
| Ossification, Heterotopic | 1 | 2009 | 16 | 0.080 |
Why?
|
| Lymphocyte Depletion | 1 | 2009 | 134 | 0.080 |
Why?
|
| Transplantation, Homologous | 2 | 2021 | 402 | 0.080 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2008 | 3 | 0.080 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2016 | 431 | 0.080 |
Why?
|
| Glycolysis | 2 | 2021 | 315 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 1 | 2008 | 26 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2010 | 813 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 171 | 0.070 |
Why?
|
| Blood Transfusion | 1 | 2010 | 295 | 0.070 |
Why?
|
| Lymphoma | 1 | 2009 | 199 | 0.070 |
Why?
|
| Intraoperative Period | 1 | 2008 | 53 | 0.070 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 5075 | 0.070 |
Why?
|
| Disease | 1 | 2009 | 95 | 0.070 |
Why?
|
| Cochlea | 1 | 2009 | 100 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 998 | 0.070 |
Why?
|
| Asthma | 1 | 2021 | 2225 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 433 | 0.070 |
Why?
|
| Cochlear Implants | 1 | 2009 | 104 | 0.070 |
Why?
|
| Alcohol Drinking | 2 | 2010 | 765 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2009 | 230 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2022 | 3378 | 0.070 |
Why?
|
| Esthetics | 2 | 2010 | 49 | 0.070 |
Why?
|
| Bayes Theorem | 1 | 2009 | 375 | 0.070 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2006 | 110 | 0.070 |
Why?
|
| Smoking | 2 | 2010 | 1500 | 0.070 |
Why?
|
| Peptide Mapping | 1 | 2006 | 63 | 0.060 |
Why?
|
| United States | 3 | 2018 | 13871 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2013 | 679 | 0.060 |
Why?
|
| DNA-Binding Proteins | 2 | 2004 | 1445 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2021 | 377 | 0.060 |
Why?
|
| Quinazolines | 1 | 2007 | 243 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 2128 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2022 | 1432 | 0.060 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2004 | 231 | 0.060 |
Why?
|
| Protein Isoforms | 1 | 2006 | 388 | 0.060 |
Why?
|
| Lovastatin | 1 | 2005 | 37 | 0.060 |
Why?
|
| Hospitals, Proprietary | 1 | 2024 | 4 | 0.060 |
Why?
|
| Hydrogen Peroxide | 1 | 2006 | 317 | 0.060 |
Why?
|
| Carcinogens, Environmental | 1 | 2004 | 7 | 0.060 |
Why?
|
| Cytodiagnosis | 1 | 2004 | 32 | 0.060 |
Why?
|
| Hospitals, Public | 1 | 2024 | 26 | 0.060 |
Why?
|
| Financing, Government | 1 | 2024 | 43 | 0.060 |
Why?
|
| Skin | 2 | 2007 | 727 | 0.060 |
Why?
|
| Haploinsufficiency | 1 | 2024 | 48 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2023 | 1269 | 0.060 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 1087 | 0.060 |
Why?
|
| Lymphopenia | 1 | 2024 | 60 | 0.060 |
Why?
|
| Models, Biological | 2 | 2009 | 1724 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1560 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 1035 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 376 | 0.050 |
Why?
|
| ras Proteins | 1 | 2004 | 144 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 441 | 0.050 |
Why?
|
| Comorbidity | 2 | 2020 | 1547 | 0.050 |
Why?
|
| Lipid Bilayers | 1 | 2024 | 97 | 0.050 |
Why?
|
| Age Factors | 3 | 2020 | 3152 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2024 | 308 | 0.050 |
Why?
|
| Risk Factors | 4 | 2020 | 9786 | 0.050 |
Why?
|
| Kinetics | 1 | 2006 | 1645 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2010 | 829 | 0.050 |
Why?
|
| Epoprostenol | 1 | 2023 | 136 | 0.050 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2023 | 199 | 0.050 |
Why?
|
| Calreticulin | 1 | 2022 | 27 | 0.050 |
Why?
|
| Viral Load | 1 | 2004 | 449 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1366 | 0.050 |
Why?
|
| Gain of Function Mutation | 1 | 2022 | 34 | 0.050 |
Why?
|
| Mammals | 1 | 2024 | 275 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2002 | 53 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2005 | 230 | 0.050 |
Why?
|
| Cell Count | 1 | 2022 | 312 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2023 | 209 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2004 | 393 | 0.050 |
Why?
|
| Income | 1 | 2023 | 188 | 0.050 |
Why?
|
| Receptors, IgG | 1 | 2022 | 73 | 0.050 |
Why?
|
| Nose Neoplasms | 1 | 2001 | 20 | 0.050 |
Why?
|
| HEK293 Cells | 1 | 2024 | 698 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2022 | 79 | 0.050 |
Why?
|
| Janus Kinase 1 | 1 | 2021 | 24 | 0.050 |
Why?
|
| Dilatation | 1 | 2022 | 61 | 0.050 |
Why?
|
| Carcinoma, Papillary | 1 | 2002 | 77 | 0.050 |
Why?
|
| Uncertainty | 1 | 2022 | 121 | 0.050 |
Why?
|
| Nose | 1 | 2001 | 63 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 851 | 0.050 |
Why?
|
| Alternaria | 1 | 2021 | 9 | 0.050 |
Why?
|
| Calgranulin B | 1 | 2021 | 9 | 0.050 |
Why?
|
| Pyroglyphidae | 1 | 2021 | 19 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2021 | 38 | 0.040 |
Why?
|
| Genome, Human | 2 | 2014 | 394 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 2021 | 88 | 0.040 |
Why?
|
| Cell Death | 1 | 2022 | 354 | 0.040 |
Why?
|
| Surgeons | 1 | 2024 | 264 | 0.040 |
Why?
|
| Surgical Wound | 1 | 2020 | 21 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 164 | 0.040 |
Why?
|
| Glutamine | 1 | 2021 | 100 | 0.040 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2021 | 58 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 430 | 0.040 |
Why?
|
| Listeriosis | 1 | 2021 | 67 | 0.040 |
Why?
|
| Tretinoin | 1 | 2021 | 130 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2021 | 107 | 0.040 |
Why?
|
| Interleukin-7 | 1 | 2020 | 59 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 164 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2015 | 939 | 0.040 |
Why?
|
| Immune System Diseases | 1 | 2020 | 34 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2021 | 84 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 185 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 201 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 370 | 0.040 |
Why?
|
| Face | 1 | 2001 | 167 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 188 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2015 | 808 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2022 | 479 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2023 | 584 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 185 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2021 | 171 | 0.040 |
Why?
|
| Listeria monocytogenes | 1 | 2021 | 123 | 0.040 |
Why?
|
| Inventions | 1 | 2019 | 18 | 0.040 |
Why?
|
| Self Concept | 1 | 2001 | 237 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 350 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 330 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 5455 | 0.040 |
Why?
|
| Logistic Models | 1 | 2024 | 1986 | 0.040 |
Why?
|
| Linear Models | 1 | 2022 | 819 | 0.040 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2019 | 15 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2019 | 148 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 208 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2021 | 391 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2000 | 285 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 263 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 587 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 379 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 723 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 4078 | 0.040 |
Why?
|
| Streptomyces | 1 | 2018 | 6 | 0.040 |
Why?
|
| Cell Extracts | 1 | 2018 | 17 | 0.040 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 646 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2020 | 356 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 122 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2017 | 88 | 0.040 |
Why?
|
| Propensity Score | 1 | 2019 | 264 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2022 | 3262 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 264 | 0.040 |
Why?
|
| Recurrence | 2 | 2013 | 1011 | 0.040 |
Why?
|
| Telomerase | 1 | 2000 | 234 | 0.040 |
Why?
|
| Mandibular Neoplasms | 1 | 2017 | 22 | 0.030 |
Why?
|
| Histones | 1 | 2022 | 589 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 334 | 0.030 |
Why?
|
| Phospholipase C gamma | 1 | 2016 | 29 | 0.030 |
Why?
|
| Rural Population | 1 | 2020 | 516 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2021 | 596 | 0.030 |
Why?
|
| Therapeutic Irrigation | 1 | 2016 | 76 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2018 | 273 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 95 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 1213 | 0.030 |
Why?
|
| Hospitals | 1 | 2021 | 637 | 0.030 |
Why?
|
| Dimyristoylphosphatidylcholine | 1 | 2015 | 1 | 0.030 |
Why?
|
| Cholesterol Esters | 1 | 2015 | 7 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2013 | 611 | 0.030 |
Why?
|
| Mesocricetus | 1 | 2015 | 38 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 423 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 276 | 0.030 |
Why?
|
| Pyrans | 1 | 2015 | 5 | 0.030 |
Why?
|
| Suspensions | 1 | 2015 | 36 | 0.030 |
Why?
|
| Brain | 1 | 2008 | 2673 | 0.030 |
Why?
|
| Cell Dedifferentiation | 1 | 2015 | 30 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 618 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2017 | 412 | 0.030 |
Why?
|
| Stem Cells | 1 | 2019 | 575 | 0.030 |
Why?
|
| Weight Loss | 1 | 2020 | 738 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 2015 | 28 | 0.030 |
Why?
|
| Cell Self Renewal | 1 | 2015 | 53 | 0.030 |
Why?
|
| CREB-Binding Protein | 1 | 2015 | 27 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2001 | 778 | 0.030 |
Why?
|
| Database Management Systems | 1 | 2015 | 48 | 0.030 |
Why?
|
| Taxoids | 1 | 2015 | 98 | 0.030 |
Why?
|
| Cell Plasticity | 1 | 2015 | 27 | 0.030 |
Why?
|
| Glucose | 1 | 2020 | 1002 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 133 | 0.030 |
Why?
|
| Accessory Nerve | 1 | 2014 | 4 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1005 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2015 | 256 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1970 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2014 | 32 | 0.030 |
Why?
|
| Benzamides | 1 | 2015 | 203 | 0.030 |
Why?
|
| Metabolome | 1 | 2018 | 340 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2015 | 315 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 2720 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 432 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2015 | 269 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2020 | 640 | 0.030 |
Why?
|
| Mitochondria | 1 | 2020 | 876 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2015 | 341 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 32 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2022 | 1468 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2015 | 452 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 898 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1891 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 2739 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2015 | 181 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 682 | 0.030 |
Why?
|
| Child | 4 | 2019 | 20884 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 282 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2015 | 363 | 0.030 |
Why?
|
| Histiocytes | 1 | 2013 | 7 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2010 | 1293 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 338 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2013 | 25 | 0.030 |
Why?
|
| E-Selectin | 1 | 2013 | 55 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 55 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2024 | 5756 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 168 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2013 | 82 | 0.030 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2012 | 32 | 0.020 |
Why?
|
| Codon | 1 | 1993 | 86 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2013 | 297 | 0.020 |
Why?
|
| Clone Cells | 1 | 2013 | 262 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2018 | 1720 | 0.020 |
Why?
|
| Gene Amplification | 1 | 1993 | 104 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 2012 | 95 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2013 | 212 | 0.020 |
Why?
|
| Gene Rearrangement | 1 | 1993 | 148 | 0.020 |
Why?
|
| Pyridines | 1 | 2015 | 478 | 0.020 |
Why?
|
| Exome | 1 | 2013 | 221 | 0.020 |
Why?
|
| Canada | 1 | 2012 | 350 | 0.020 |
Why?
|
| Cell Separation | 1 | 2013 | 317 | 0.020 |
Why?
|
| Exons | 1 | 1993 | 342 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 502 | 0.020 |
Why?
|
| Data Mining | 1 | 2012 | 110 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 481 | 0.020 |
Why?
|
| Interleukins | 1 | 2013 | 241 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2021 | 2100 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2542 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2013 | 300 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 949 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2010 | 26 | 0.020 |
Why?
|
| Forehead | 1 | 2010 | 6 | 0.020 |
Why?
|
| Scalp | 1 | 2010 | 34 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1491 | 0.020 |
Why?
|
| Skin Transplantation | 1 | 2010 | 84 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 356 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 1993 | 637 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 306 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 419 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 797 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2013 | 487 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 2009 | 86 | 0.020 |
Why?
|
| U937 Cells | 1 | 2009 | 24 | 0.020 |
Why?
|
| SEER Program | 1 | 2010 | 202 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 503 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 661 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2008 | 32 | 0.020 |
Why?
|
| Models, Anatomic | 1 | 2009 | 87 | 0.020 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2008 | 19 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 147 | 0.020 |
Why?
|
| Lung | 1 | 2021 | 3938 | 0.020 |
Why?
|
| Wound Healing | 1 | 2010 | 307 | 0.020 |
Why?
|
| Graft Survival | 1 | 2010 | 513 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2008 | 75 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 5415 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 337 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2007 | 70 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2007 | 74 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2010 | 598 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 1250 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 169 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2009 | 426 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2019 | 10490 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 2011 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2004 | 27 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 2003 | 54 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2009 | 1125 | 0.010 |
Why?
|
| Norway | 1 | 2002 | 42 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 2002 | 20 | 0.010 |
Why?
|
| Antigens | 1 | 2004 | 356 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2002 | 30 | 0.010 |
Why?
|
| Papilloma, Inverted | 1 | 2001 | 3 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2001 | 28 | 0.010 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2001 | 12 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2002 | 108 | 0.010 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2001 | 14 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2001 | 212 | 0.010 |
Why?
|
| Methylation | 1 | 2001 | 230 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 511 | 0.010 |
Why?
|
| Laryngeal Mucosa | 1 | 2000 | 8 | 0.010 |
Why?
|
| Densitometry | 1 | 2000 | 34 | 0.010 |
Why?
|
| Ribonucleases | 1 | 2000 | 54 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2002 | 1019 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2002 | 1198 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2000 | 339 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2001 | 399 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2001 | 745 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2001 | 1207 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2000 | 953 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 1098 | 0.010 |
Why?
|